SLN.L Share News (SLN)
SLN Share
SLN Share
SLN Share
SLN Share
SLN
SLN Share
SLN Broker
SLN Directors
SLN Financial
SLN
SLN Short
SLNTue, 08th Sep 2020 19:23
Silence Therapeutics PLC - novel RNA therapeutics developer - Listing of American depositary shares on Nasdaq approved. Also reports SLN360 candidate for treatment of cardiovascular disease receives approval from US Food & Drug Administration for an investigational new drug application.
Current stock price: 470.00 pence
Year-to-date change: up 34%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
IN BRIEF: Silence Therapeutics to delist from AIM next week
Read more
(Sharecast News) - Silence Therapeutics updated the market on the planned cancellation of its shares on AIM on Friday, which it originally announced on 15 October.
Read moreTRADING UPDATES: Focusrite profit jumps; Gear4Music strikes bum note
Read more(Sharecast News) - Silence Therapeutics said on Tuesday that its revenue increased by £1.2m year-on-year in its third quarter, as a result of the further advancement of its partner programmes, as well as the introduction of additional programmes with its partners.
Read moreIN BRIEF: Frazier Life picks up 3% interest in Silence Therapeutics
Read more(Sharecast News) - Novel short interfering ribonucleic acid (siRNA) therapy developer Silence Therapeutics announced on Friday that healthcare-focussed investor Frazier Life Sciences Public Fund had purchased about $20m of its existing shares.
Read moreUK shareholder meetings calendar - next 7 days
Read moreIN BRIEF: Silence Therapeutics reports solid progress across pipelines
Read moreCORRECT: Silence Therapeutics to delist from AIM; teams with Hansoh
Read moreIN BRIEF: Silence Therapeutics to delist from AIM; unites with Hansoh
Read more(Sharecast News) - Silence Therapeutics announced a collaboration with Hansoh Pharmaceutical Group on Friday, to develop short interfering ribonucleic acids (siRNAs) for three undisclosed targets, leveraging its proprietary 'mRNAi GOLD' platform.
Read more(Sharecast News) - Silence Therapeutics announced the appointment of John Strafford to the newly-created role of senior vice-president of business development, alliance management and new product development on Wednesday, effective immediately.
Read moreIN BRIEF: Silence Therapeutics revenue up, new targets with AstraZeneca
Read more(Sharecast News) - Silence Therapeutics reported revenues from collaborations of £5.8m in its first half on Thursday, up from £1.1m year-on-year, which it put down to its work with AstraZeneca and Mallinckrodt.
Read moreUK earnings, trading statements calendar - next 7 days
Read more